Women health med-tech Biorithm bags US$3.5 million in Series A

SINGAPORE-BASED global women’s heath startup, Biorithm, has closed US$3.5 million in Series A funding.

The funding round was co-led by new investor Adaptive Capital Partners and existing investor Seeds Capital, said the med-tech company on Monday (Dec 18).

The funding will be used to enhance the company’s expansion plan, firstly across South-east Asia and then in the United States. It will also be used to further research to improve patient experience.

“Having successfully completed clinical trials with healthcare institutions in Singapore and the United Kingdom, Biorithm will be expanding its clinical trial footprint to more of its priority markets,” said the startup headquartered in both Singapore and Boston. It also aims to foster various global partnerships to strengthen the women’s health ecosystem.

“We are excited to continue backing Biorithm as they accelerate their commercialisation in the US and support their vision of revolutionising the global maternal health market,” said Tan Kaixin, general manager of Seeds Capital, the investment arm of Enterprise Singapore.

“Investments in med-tech startups like Biorithm will propel the healthcare ecosystem to new heights,” Tan added.